Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Serotonin 5-HT6 antagonist PRX-07034 begins phase I study

June 9, 2006

Enrollment opens in phase II study of AL-208 for CABG-associated MCI

June 9, 2006

Data from trial of eszopiclone in insomniac patients with depression further analyzed

June 9, 2006

PF-670462: new potent CKIe inhibitor evokes phase delays

June 9, 2006

Progesterone may be of benefit in treating brain trauma

June 9, 2006

Betaferon approved in Europe as first-line treatment for earliest stages of MS

June 8, 2006

Abilify launched in Japan

June 8, 2006

AZ-001 studied in phase IIb trial for migraine

June 8, 2006

Stimulant medications most effective in treating attention deficit hyperactivity disorder

June 8, 2006

Phase III results of lisdexamfetamine in ADHD presented

June 8, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.